🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against superbug strains of the pathogen, according to scientists.

An International Health Concern

Gonorrhoea infections are on the rise around the world, with figures suggesting over 82 million instances each year. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the face of rising global incidence, escalating drug resistance and the highly restricted available drugs currently available.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

Zoliflodacin, marketed under the name a brand name, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in concurrent days. This treatment, which is additionally indicated for UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This approval signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Outcomes and Worldwide Availability

As per findings released by a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an equal footing with the typical regimen, which combines a dual-drug approach. The research included over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the rights to license and sell the drug in a wide range of developing nations.

Medical professionals directly involved have expressed positive views. The availability of a one-pill regimen like this is hailed as a "game-changer" for public health efforts. This is deemed essential to reduce the burden of the illness for people and to halt the transmission of extremely resistant gonorrhoea worldwide.